Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.

Publication Type:

Journal Article


AIDS (London, England), Volume 25, Issue 2, p.153-8 (2011)


2011, Adenoviridae Infections, Adenoviruses, Human, Adult, Africa, AIDS Vaccines, Antibodies, Neutralizing, Case-Control Studies, Female, Genetic Vectors, HIV Seropositivity, HIV-1, Humans, Male, Risk Assessment, South America, United States, Vaccine and Infectious Disease Division


adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition.